Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes

Table 1 Demographics and treatment of the 65 eyes

Categorical Variables		Switch (N = 52)		Naïve (N = 13)		P-value
Categorical Variables		N	%	N	%	P-value
Gender	Male	16	30.7	3	23.1	0.595
Gender	Female	36	69.3	10	76.9	0.595
Fellow-eye Status	iAMD	18	34.6	5	38.5	0.064
	nAMD	25	48.0	8	61.5
	cRORA	9	17.4	0	0.0
Drusen Phenotype	Drusen	39	34.6	11	38.5	0.371
	SDD	2	48.0	0	61.5
	Drusen + SDD	11	17.4	2	0.0
PED Phenotype	Fibrovascular	38	73.1	7	53.8	0.147
PED Phenotype	Serous	14	26.9	6	46.2
Onset of AEs	RPE tear	1	1.9	1	16.7	0.281 -
Onset of AEs	IOI	0	0.0	0	0.0	0.281 -
Metric Variables		Mean	SD	Mean	SD	P-value
BCVA (ETDRS)	Baseline	75.5	9.58	69.2	9.54	0.022*
BCVA (ETDRS)	12-month	76.0	10.0	76.1	13.7	0.535
IVT (n)	Previous Anti-VEGF	40.4	37.7	0.0	0.00	< 0.001*
IVT (n)	Faricimab	8.3	2.5	6.0	2.7	0.009*

Legenda – iAMD: intermediate age-related macular degeneration; nAMD: neovascular AMD; cRORA: complete RPE and outer retinal atrophy; SDD: subretinal drusenoid deposits.; AEs: adverse events; RPE tear: retinal pigment epithelium tear; IOI: intraocular inflammation; ETDRS: early treatment diabetic retinopathy study; IVT: intravitreal treatment number; Anti-VEGF: anti-vascular endothelial growth factor agents i.e., Aflibercept, Brolucizumab and Ranibizumab; SD: standard deviation; p-value: probability level derived by the chi-squared test for categorical variables, and by the Mann-Whitney Test for metric variables;

ISSN: 2056-9920